Alzheimer Disease   |   Diabetes   |   Erectile Dysfunction   |   Hypogonadism   |   Migraine   |   Overactive Bladder

CME Certificate Registration and Pretest

CME credit is offered upon successful completion of the Posttest with a minimum score of 70%
and submission of the Evaluation after the activity.

Please complete the form below to register for this activity. Your CME certificate will be issued
from the following information.

(*) indicates a required field.

Business  Personal
Because you have attended or shown interest in our programs, we may send you information on this
and similar programs utilizing the e-mail address provided. You may unsubscribe at any time by
clicking on the “unsubscribe” link on any e-mails received from us.

Please do not send me information via e-mail.

Privacy Policy
We value the confidentiality of the information you choose to share with us and are committed to its protection. All
personal information you provide is stored in a secure location and will never be sold or distributed to any third party.


All fields are required. Select the best answer to each question.

1.Which of the following may increase sensitivity of early detection of amyloid-β (Aβ) pathology in Alzheimer disease (AD) but is not required by current diagnostic guidelines?
History of gradual progression of memory impairment
Cognitive impairment sufficient to interfere with social or occupational functioning
Presence of a biomarker of neuronal degeneration (eg, elevated cerebrospinal fluid [CSF] tau, decreased fluorodeoxyglucose positron emission tomography uptake, or atrophy on magnetic resonance imaging)
Presence of a biomarker of amyloid pathology (eg, reduced CSF Aβ1-42 or a positive amyloid imaging scan)
2.Treatment with acetylcholinesterase inhibitors, if effective, provides which of the following benefits in patients with mild to moderate AD?
Prevention of progression of cognitive impairment
Stabilization of cognitive and functional abilities
Prevention of proliferation of neuritic plaques and tangles
Marked enhancement of cognitive function
3.What is the sequence of AD pathologies proposed in the amyloid cascade hypothesis?
Tau neurofibrillary tangle (NFT) formation, Aβ deposits, neuronal loss
Neuronal loss, synapse loss, Aβ deposits
Aβ deposits, tau NFT formation, neuronal loss
Inflammation, mitochondrial dysfunction, synapse loss
4.Which class of disease-modifying therapy for AD decreases Aβ production?
Aβ antagonist
Anti-Aβ antibodies
Secretase inhibitors
None of the above
5.Which characteristic of anti-Aβ monoclonal antibodies may preferentially mobilize soluble Aβ species from the brain, thereby fostering peripheral clearance?
Binding to central domain of Aβ peptide
Binding to amino terminus of Aβ peptide
Binding to carboxy terminus of Aβ peptide
Binding to carboxy terminus of tau peptide


© 2012 CogniMed Inc. All rights reserved.                                                                            AZ14001                                                                          September 2012

Jointly sponsored by and
This activity is supported by an independent
educational grant provided by Lilly USA, LLC.

© 2012 CogniMed Inc. All rights reserved.